Reaction Biology Corp. (RBC) provides drug profiling, screening and early-stage drug discovery collaborations. The firm's proprietary HotSpot technology is an innovative high-throughput platform for screening and profiling small molecules against any biological target, which may be assayed by radioisotope detection. For kinase and transferase enzymes in particular, such assays are recognized as the "gold standard". RBC is the first and only CRO to provide screening and profiling vs. all major classes of epigenetic transferases via the radioisotope approach-histone lysine and arginine methyltransferases (HMTs), DNA methyltransferases (DNMTs), Histone acetylases (HATs), and histone-modifying and almost all other kinases. All HotSpot assay substrates require no special modifications (e.g. biotin, fluorophors or other tags). Hence biologically relevant substrates may be used, including full nucleosomes, histone proteins or peptides. Since detection does not rely on antibodies, coupling enzymes or fluorescence, major causes of false positives, false negatives and compound interference are eliminated. RBC also offers fluorescence-based detection for all HDAC and Sirtuin isoforms with a variety of substrates. RBC takes a comprehensive approach to serving the epigenetic drug discovery industry, providing high quality proteins; robust and low cost assay development, library screening, drug profiling and validation of drug activity in cellular assays. RBC specializes in screening and profiling kinases, HDAC's, methyltransferases, and providing custom assay development
